Risks And Benefits Of Breast Cancer Screening: BreastScreen WA Cohort Study Of Overdiagnosis And Breast Cancer Mortality
Funder
National Health and Medical Research Council
Funding Amount
$201,524.00
Summary
Overdiagnosis is the major downside of screening for breast cancer. This occurs when screening detects cancers that would not have caused symptoms in the woman's lifetime. This study aims to quantify the amount of overdiagnosis that occurs in the Australian breast cancer screening program (BreastScreen)
Activation Of BMP4 Signalling To Inhibit Breast Cancer Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$748,742.00
Summary
The spread of cancer cells to other organs is a common cause of breast cancer-related death in women. Current therapies for advanced breast cancer are often palliative since the secondary tumours become resistant to the chemotherapy. Here, we are using preclinical models of advanced breast cancer to develop a treatment that should be effective in patients with secondary tumours and should reduce the risk of dying of this disease.
Combining PI3K, CDK4/6 Pathway Inhibitors And Immunotherapies In Triple-negative Breast Cancer (TNBC): A Novel Therapy Combination
Funder
National Health and Medical Research Council
Funding Amount
$626,345.00
Summary
Triple-negative breast cancer (TNBC) has the worst prognosis of all breast cancer subtypes, classically affecting young women and characterized by a lack of effective therapies. We show that blocking both PI3K and CDK4/6 pathways together effectively reduces TNBC growth in mice and can enhance anti-tumour immune responses. We aim to understand how these drugs work together and if adding immunotherapy can improve responses. Our project could provide a new treatment approach for TNBC patients.
Improved And Automated Measures Of Breast Cancer Risk Based On Digital Mammography And Family History Data Collected By BreastScreen That Will Enable Tailored Screening For Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$741,180.00
Summary
We will use mammograms and family history information collected by BreastScreen to update and improve our automated measures of mammographic density for the new era of digital mammograms. We will then develop a new risk prediction tool by combining the measure of mammographic density for digital mammograms with other risk factors so that information on risk can be given to women at the time of their scans. The results of this project will enable Australian women to receive tailored screening.
Statistical Analysis Of An International 10 Year Prospective Family Study Of Gene-environment Interactions On Risk Of Female Breast Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$450,198.00
Summary
This study will provide new and credible information on how the effects of environmental and lifestyle factors on breast cancer risk depend on a woman's underlying genetic susceptibility using a large, international 10 year prospective family study.
Interplay Between Metabolic Reprogramming And Oncogenic Signalling In The Cellular Response To Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$654,035.00
Summary
Chemotherapy resistance is a major barrier to the treatment of triple-negative breast cancer (TNBC). We seek to uncover an intimate link between cell metabolism and oncogenic signalling pathways in regulating the cellular response to chemotherapy. Our studies will identify a critical mechanism limiting the therapeutic efficacy of chemotherapy and investigate combination therapy strategies that could improve the treatment of TNBC.
Do Breast Cancer Risk Factors Differ According To Underlying Genetic Susceptibility? A Pooled Analysis Of Prospective Studies From The NCI Cancer Cohort Consortium
Funder
National Health and Medical Research Council
Funding Amount
$418,581.00
Summary
We propose to use data from 23 international prospective cohort studies in the Cancer Cohort Consortium organised by the US National Cancer Institute to evaluate gene environment interactions for women who are at increased genetic risk of breast cancer. Our ultimate goal is to enhance the performance of clinical prediction tools and to develop targeted evidence-based strategies to mitigate the high absolute risk of breast cancer for women at increased genetic risk of the disease.
The Role Of CD73 In Cancer: Validating A Novel Therapeutic Target
Funder
National Health and Medical Research Council
Funding Amount
$540,356.00
Summary
We here propose to investigate the role of a specific immune-suppressive molecule called CD73 in cancer. We will test the therapeutic activity of blocking CD73 with a monoclonal antibody for cancer treatment, either used alone or in combination with immune-activating agents and chemotherapy.
Targeting Bone Marrow Mediated Angiogenesis And Metastasis In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$463,006.00
Summary
Despite advances in treatment and diagnostics breast cancer (BC) remains one of the leading causes of death in women. Metastases and tumour blood vessel recruitment are linked. Work by Dr Mellick and others has shown that host bone marrow contributes endothelial progenitor cells (EPCs) to tumour vasculature. The chemokines and their receptors, which differentiate EPCs from tumour vessels, will be knocked down in the tumour cells and EPC progenitors with the aim of preventing tumour spread.
Characterisation Of Eurl, A Novel Gene Implicated In The Etiology Of Abnormal Brain Development And Intellectual Disability
Funder
National Health and Medical Research Council
Funding Amount
$597,541.00
Summary
Intellectual disability affects around one per cent of Australians, and can arise from genetic abnormalities during fetal life, such as through abnormal regulation of gene expression. We have identified a novel gene, known as eurl, which controls brain assembly as well as the ability of neurons to form functional connections within the brain. We will investigate how this novel gene controls brain development, and characterise eurl as a potential therapeutic target for learning and memory.